9 Clinical Trials for Various Conditions
* Hypothesis 1: Food allergies are associated with poor growth which can be corrected with nutrition intervention. * More than 10% of children with multiple food allergies will have a weight-for-age z-score less than - 2 at diagnosis. The z-score is a measure of the distance from the mean value, or 50th percentile on the growth chart. A z-score of less than - 2 indicates that the child is underweight. * Growth parameters of children with multiple food allergies will improve after intervention by a team that includes a dietitian and an allergist. * Hypothesis 2: Food allergies are associated with low micronutrient intake which can be corrected with nutrition intervention. o More than 30% of children with multiple food allergies will consume less than 67% of the Dietary Reference Intake for at least one macronutrient or micronutrient at diagnosis. * Macronutrient and micronutrient intake will increase after intervention by a team that includes a dietitian and an allergist. o • Hypothesis 3: Food allergies are related to behavioral feeding problems which can be corrected with nutrition intervention. * At least 25% of children with multiple food allergies will have behavioral feeding problems at diagnosis. * Prevalence of behavioral feeding problems will decrease after nutrition intervention.
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergic to more than two other foods, the primary endpoint/outcome in this study will only be assessed in peanut and two other foods for each participant. The primary objective of the study is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC), after treatment with either omalizumab or placebo for omalizumab.
To assess the frequency and nature of adverse events in infants fed a free amino acid based infant formula.
This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.
The Primary Objective of the study is to develop a customized regimen for oral immunotherapy that reflects what the subject is allergic in a clinically significant way (i.e., the offending food allergen is defined as a food allergen with a positive skin test or positive specific IgE and a positive DBPCFC). Therefore, the investigators prefer that both single and multiple food allergy subjects are included in the study.
This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food allergies (limited to 5 of those food allergens in IND 14831). In a 3:1 ratio, 36\* participants will receive Xolair for 16 weeks while 12\* will receive corresponding placebo instead of Xolair. 12 controls will be enrolled who will receive no OIT and no Xolair. These 12 controls are not part of the randomization. The total number of participants randomized to the two arms is 48\*.
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.